Naloxone hydrochloride; pentazocine hydrochloride - Generic Drug Details

What are the generic sources for naloxone hydrochloride; pentazocine hydrochloride and what is the scope of freedom to operate?

Naloxone hydrochloride; pentazocine hydrochloride is the generic ingredient in two branded drugs marketed by Lupin, Sun Pharm Inds Ltd, Watson Labs, and Sanofi Aventis Us, and is included in four NDAs. Additional information is available in the individual branded drug profile pages.

Three suppliers are listed for this compound.

Summary for naloxone hydrochloride; pentazocine hydrochloride

US Patents:	0
Tradenames:	2
Applicants:	4
NDAs:	4
Finished Product Suppliers / Packagers:	3
Clinical Trials:	2
DailyMed Link:	naloxone hydrochloride; pentazocine hydrochloride at DailyMed

Recent Clinical Trials for naloxone hydrochloride; pentazocine hydrochloride

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
National Institute on Aging (NIA)	Phase 1
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	Phase 1
Office of Research on Women's Health (ORWH)	Phase 1

See all naloxone hydrochloride; pentazocine hydrochloride clinical trials

Pharmacology for naloxone hydrochloride; pentazocine hydrochloride

Drug Class	Opioid Antagonist Partial Opioid Agonist/Antagonist
Mechanism of Action	Competitive Opioid Antagonists Opioid Antagonists Partial Opioid Agonists

Anatomical Therapeutic Chemical (ATC) Classes for naloxone hydrochloride; pentazocine hydrochloride

A06AH	Peripheral opioid receptor antagonists
A06A	DRUGS FOR CONSTIPATION
A06	DRUGS FOR CONSTIPATION
A	Alimentary tract and metabolism

N02AD	Benzomorphan derivatives
N02A	OPIOIDS
N02	ANALGESICS
N	Nervous system

V03AB	Antidotes
V03A	ALL OTHER THERAPEUTIC PRODUCTS
V03	ALL OTHER THERAPEUTIC PRODUCTS
V	Various

US Patents and Regulatory Information for naloxone hydrochloride; pentazocine hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Lupin	NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE	naloxone hydrochloride; pentazocine hydrochloride	TABLET;ORAL	075735-001	Jul 11, 2001	AB	RX	No	No
Sanofi Aventis Us	TALWIN NX	naloxone hydrochloride; pentazocine hydrochloride	TABLET;ORAL	018733-001	Dec 16, 1982		DISCN	No	No
Sun Pharm Inds Ltd	NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE	naloxone hydrochloride; pentazocine hydrochloride	TABLET;ORAL	075523-001	Mar 17, 2000	AB	RX	No	No

Expired US Patents for naloxone hydrochloride; pentazocine hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Sanofi Aventis Us	TALWIN NX	naloxone hydrochloride; pentazocine hydrochloride	TABLET;ORAL	018733-001	Dec 16, 1982	4,105,659

Market Dynamics and Financial Trajectory for Nalozone Hydrochloride and Pentazocine Hydrochloride

Last updated: February 15, 2026

Overview of Nalozone Hydrochloride and Pentazocine Hydrochloride

Nalozone Hydrochloride is an opioid antagonist used primarily to reverse opioid overdose in emergency settings. It is an essential medication in overdose management, especially amidst rising opioid-related fatalities.

Pentazocine Hydrochloride is an analgesic with mixed opioid agonist-antagonist properties indicated for moderate to severe pain. It is often used in clinical settings with considerations to its abuse potential.

Market Landscape and Drivers

Nalozone Hydrochloride

Market Size:

• The global naloxone market was valued at approximately USD 200 million in 2022.
• Expected Compound Annual Growth Rate (CAGR): 6.8% from 2023 to 2030.

Drivers:

• Rising opioid overdose deaths: The CDC reports over 107,000 opioid-related deaths in the U.S. in 2021, up 15% from 2020. This amplifies demand for naloxone [1].
• Widening accessibility: Governments and health organizations expand distribution programs.
• Policy changes: U.S. FDA approvals for intranasal formulations in 2015 and 2019 facilitated broader availability.

Market Segments:

• Formulations: Injectable, intranasal, auto-injectors.
• End users: Emergency responders, hospitals, community programs.

Competitive Environment:

• Major players include Mylan (now part of Viatris), Teva Pharmaceuticals, and Kaleo, with a maturing landscape dominated by established generic manufacturers.

Pentazocine Hydrochloride

Market Size:

• The global analgesic market was valued at USD 20 billion in 2022, with pentazocine constituting a small fraction primarily in specific markets.
• Market growth rates are modest, predominantly driven by regional prescribing trends.

Drivers:

• Niche use in pain management where other opioids are contraindicated.
• Regulations limiting opioid use curb pentazocine prescribing.
• Regulatory restrictions due to abuse potential.

Market Challenges:

• Abuse and dependence risks lead to restrictions and decreased prescribing.
• Competition from other analgesics (e.g., morphine, oxycodone, NSAIDs).
• Limited patent protection; many formulations are generic.

Regional Trends:

• Usage remains relatively prevalent in India and Southeast Asia.
• Western markets see limited use due to strict controls and preference for other opioids.

Regulatory and Policy Impact

• Nalozone Hydrochloride:
  • U.S. FDA approval for intranasal formulations in 2015 (Narcan) increased adoption.
  • Several countries have enacted standing orders or OTC availability for naloxone to combat overdose mortality.
• Pentazocine Hydrochloride:
  • Classified as a controlled substance in most countries (Schedule IV in the U.S.).
  • Regulations tighten prescribing due to noted abuse cases.

Financial Trajectory and Market Opportunities

Nalozone Hydrochloride

Projected to outperform in revenue growth owing to increasing overdose incidents and policy shifts toward wider naloxone use. Market expansion includes:

• Higher adoption of auto-injectors and intranasal devices.
• Collaboration with governmental agencies for large-scale distribution programs.
• Potential new formulations (e.g., longer-acting formulations).

Financial outlook:

• Revenue estimated to reach USD 340 million by 2030, with increasing profit margins driven by generic competition and scale.

Pentazocine Hydrochloride

Growth prospects are limited; the market remains small and regional:

• Growth depends on regional prescribing policies, especially in countries with higher opioid use.
• Decline expected in Western markets due to restrictions and the shift toward alternative analgesics.

Financial outlook:

• Market value stagnates or declines marginally; is heavily dependent on regional demand and regulatory frameworks.

Competitive Analysis

Parameter	Nalozone Hydrochloride	Pentazocine Hydrochloride
Market Size (2022)	USD 200 million	Data scarce; regional markets, USD millions
CAGR	6.8% (2023-2030)	Flat or declining in key markets
Key Players	Viatris, Teva, Kaleo	Various regional generic manufacturers
Regulatory Status	Increasing support via policies	Restricted due to abuse potential

Key Challenges

• For naloxone: price pressures, supply chain stability, and ensuring access in low-resource settings.
• For pentazocine: regulatory constraints, abuse potential, and market saturation limits.

Conclusion

Nalozone Hydrochloride is positioned for sustained growth driven by the opioid overdose crisis, regulatory support, and expanding distribution channels. Pentazocine Hydrochloride faces market contraction threats due to regulatory restrictions and shifting prescribing patterns but retains regional relevance.

---

Key Takeaways

• The naloxone market is expanding globally amid increasing overdose mortality, with innovative formulations and distribution programs propelling revenue growth.
• The pentazocine market is shrinking in developed regions, with limited growth opportunities. Regional markets like India maintain some demand.
• Regulatory environments heavily influence both products, with naloxone benefiting from policy support and pentazocine constrained by abuse risks.
• Top players for naloxone include Viatris and Kaleo, focusing on scalability and new delivery systems.

---

FAQs

1. What factors are driving the growth of the naloxone market?
Rising opioid overdose deaths, policy support for wider access, and innovations in delivery systems are primary drivers.

2. How does regulatory change impact pentazocine's market?
Stringent restrictions on opioid use limit prescribing, reducing market size and growth potential for pentazocine.

3. Are there new formulations of naloxone in development?
Yes, longer-acting formulations and auto-injectors are ongoing development areas to improve compliance and accessibility.

4. Which regions are most significant for naloxone sales?
North America dominates, especially the U.S., with expanding markets in Europe and some APAC countries.

5. Is pentazocine still widely used?
In certain regions like India, it remains in use for specific pain indications, but overall usage declines in developed markets due to regulation.

---

Sources

[1] CDC National Center for Health Statistics, 2022 Data.